Page 24 - Read Online

Page 148 Eitan et al. Extracell Vesicles Circ Nucleic Acids 2023;4:133-150 https://dx.doi.org/10.20517/evcna.2023.13

Availability of data and materials
De-identified data will be made available to qualified investigators upon request.

Financial Support and Sponsorship
This research was supported in part by the Intramural Research Program of the National Institute on Aging
(NIA/NIH) and through a three-way Collaborative Research and Development Agreement between NIA,
Alkermes, and NeuroDex.

Conflict of interest
Dr. Eitan, Dr. Elgart, Dr. Volpert, and Ms. Gershun are affiliates of NeuroDex, a for-profit company. The
work reported below was performed as part of their paid employment. Dr. Eitan holds stocks for NeuroDex.
Dr. Thornton-Wells, Dr. Azadeh, and Dr. Smith are affiliated with Alkermes, a for-profit company. The
work reported below was performed as part of their paid employment. Dr. Erden and Dr. Kapogiannis are
affiliates of NIA, a Government Agency, they received no funds or stocks from NeuroDex or Alkermes, and
the work reported was performed as part of their Official Duties.

Ethical Approval and Consent to Participate
This study relied on retrospectively collected de-identified samples from commercial or federal government
(NIA, Baltimore, MD) biobanks. BioIVT and precision for medicine adhere to the most current regulations
for sample collection accepted in the field. The regulatory requirements include Institutional Review Board
(IRB) approval, privacy officer authorization, appropriate government licenses, and industry accreditations,
as applicable. They also adhere to the General Data Protection Regulations. Samples from the NIA were
collected through NIH IRB-approved protocols, and their use in this research is allowed based on the
subjects’ original consent. Regarding patients with AD, legally authorized representatives or patients with
consent capacity consented to participate in the original studies. All samples were de-identified prior to
their transfer to NeuroDex for processing.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y)
2019;5:272-93. DOI PubMed PMC
2. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med 2023;388:9-21. DOI PubMed
3. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 2019;14:32. DOI PubMed
PMC
4. Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther 2014;6:82. DOI PubMed PMC
5. Hogan DB, Fiest KM, Roberts JI, et al. The Prevalence and incidence of dementia with lewy bodies: a systematic review. Can J
Neurol Sci 2016;43 Suppl 1:S83-95. DOI PubMed
6. Jack CR Jr, Bennett DA, Blennow K, et al; Contributors. NIA-AA research framework: toward a biological definition of Alzheimer’s
disease. Alzheimers Dement 2018;14:535-62. DOI PubMed PMC
7. Hampel H, O'Bryant SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev
Neurol 2018;14:639-52. DOI PubMed PMC
8. Croft PK, Sharma S, Godbole N, Rice GE, Salomon C. Ovarian-cancer-associated extracellular vesicles: microenvironmental
regulation and potential clinical applications. Cells 2021;10:2272. DOI PubMed PMC
9. Delgado-Peraza F, Nogueras-Ortiz CJ, Volpert O, et al. Neuronal and astrocytic extracellular vesicle biomarkers in blood reflect brain
pathology in mouse models of Alzheimer’s disease. Cells 2021;10:993. DOI PubMed PMC
10. Kapogiannis D, Mustapic M, Shardell MD, et al. Association of extracellular vesicle biomarkers with alzheimer disease in the